Enovis Reports $1.05 Billion Goodwill Impairment and Significant Full-Year Loss; Issues 2026 Guidance

summarizeSummary

The most significant aspect of this filing is the massive $1.05 billion non-cash goodwill impairment charge for the full year 2025, which resulted in a GAAP net loss of $1.18 billion. This impairment, representing a substantial portion of the company's market capitalization, indicates a significant re-evaluation of the carrying value of its Reconstructive and Prevention & Recovery reporting units, likely stemming from prior acquisitions. While the company demonstrated solid operational performance with 6% organic sales growth and positive adjusted EBITDA and EPS for 2025, the impairment overshadows these achievements, raising concerns about asset valuation and past strategic investments. Investors should scrutinize the underlying reasons for the impairment and its long-term implications for the balance sheet and future profitability. The provided 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS will be key for assessing the company's path forward after this significant write-down.

check_boxKey Events

• Enovis Goodwill Impairment

  Enovis recorded a non-cash goodwill impairment charge of $1.05 billion for the full year 2025, significantly impacting its financial results.

• Substantial Full-Year Net Loss

  The company reported a GAAP net loss from continuing operations of $1.18 billion, or $(20.72) per share, for the full year 2025.

• Solid Organic Sales Growth

  Despite the losses, full-year 2025 net sales grew 7% on a reported basis and 6% organically to $2.2 billion.

• Positive Adjusted Earnings

  Adjusted diluted earnings per share for full-year 2025 were $3.30, with adjusted EBITDA reaching $403 million.

auto_awesomeAnalysis

The most significant aspect of this filing is the massive $1.05 billion non-cash goodwill impairment charge for the full year 2025, which resulted in a GAAP net loss of $1.18 billion. This impairment, representing a substantial portion of the company's market capitalization, indicates a significant re-evaluation of the carrying value of its Reconstructive and Prevention & Recovery reporting units, likely stemming from prior acquisitions. While the company demonstrated solid operational performance with 6% organic sales growth and positive adjusted EBITDA and EPS for 2025, the impairment overshadows these achievements, raising concerns about asset valuation and past strategic investments. Investors should scrutinize the underlying reasons for the impairment and its long-term implications for the balance sheet and future profitability. The provided 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS will be key for assessing the company's path forward after this significant write-down.